Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients. - Wikidata - wikimedia - TriplyDB

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

http://www.wikidata.org/entity/Q37994343

about

Breakthrough cancer pain - still a challenge Single-dose fentanyl sublingual spray for breakthrough cancer pain Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.

P2860

Q36429904-B2FAC7BF-C8EC-4857-BDF7-68E95E3D6E5C Q37053311-A989DB69-2E1B-4F89-9A57-89627BCD47C0 Q39214375-303F1FF4-3CF8-43B0-B7C6-FB96469ABAA5

P2860

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

http://www.wikidata.org/entity/Q37994343

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@en

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@nl

type

label

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@en

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@nl

prefLabel

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@en

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@nl

P1433

Q37994343-3FDBACC0-53BC-4ABD-B03F-930D4B72C821

P1476

Q37994343-52E2EE67-F963-4FA1-8A05-24C2DD90E139

P2860

Q37994343-034DA79E-F620-403C-80F8-4BEA6F6B5BED

Q37994343-0844BC8B-64E2-4F0B-8C2E-93F87E2FA867

Q37994343-2A7CD8AB-E172-4BE6-AFA6-F3D8797EBFB7

Q37994343-2DD84BBB-0751-477F-864B-0C8F1657E1B3

Q37994343-35776352-88C8-45AB-A15F-B13B77186405

Q37994343-36AE075A-CF61-49C4-9DD1-0203CBA5FF1C

Q37994343-3C11700D-4C3D-4614-AE17-24432EDB452D

Q37994343-3F213AA2-CBA7-40F9-8DEB-7C02402E6C18

Q37994343-4A051C48-FBF4-4CDA-A9FE-F8CA3982C32A

Q37994343-6E3FD036-226A-4EEC-9F39-95E7FBA79CD8

P304

Q37994343-10035DC6-8C5C-47B8-9797-1AF4F0C58F8B

P31

Q37994343-8E3D80FB-5753-43B3-A4B0-18ECFE340C2E

P356

Q37994343-95E6B84C-726B-4BEC-971F-A9F9678503D4

P407

Q37994343-97E6C666-059B-4371-A7B8-EB9BB24BDFE2

P433

Q37994343-28E4BE2E-D6A1-47E2-84B4-BA94C4991FC2

P478

Q37994343-03D95147-5BED-453D-B1DA-E45070BDA212

P50

Q37994343-9686BB82-2EC2-46CE-9573-90049438BC2C

P577

Q37994343-8C5B2739-0DFF-450A-B502-605B5A011CEF

P5875

Q37994343-8782C7E6-989A-472A-AF07-29FDA2438F50

P698

Q37994343-49E7FDCE-CA35-44BA-B120-EA5D0A7BA633

P921

Q37994343-8DB6BD0F-C72A-4687-92F5-8EDF0E77B5C7

P356

14656566.2012.663353

P1433

Expert Opinion on Pharmacotherapy

P1476

Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.

@en

P2860

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials.

Breakthrough pain: definition, prevalence and characteristics.

Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series.

Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.

Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines.

The performance of nanocarriers for transmucosal drug delivery.

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.

The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland.

The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.

P304

873-878

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2012.663353

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Sebastiano Mercadante

P577

2012-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221712982

http://www.w3.org/2001/XMLSchema#string

P698

22424558

http://www.w3.org/2001/XMLSchema#string

P921